Investors

Flagship Ventures

Flagship Ventures is an early-stage venture capital firm focused on creating, financing, and building innovative companies in the Life Science and Technology sectors. Headquartered in Cambridge, MA, Flagship Ventures was founded in 1999 and manages $700 million in capital. Prior to its founding, Flagship's principals were involved as founders or investors in over 100 firms, including Adolor, AltaVista, Anesta, Antigenics, Aspect Medical, Astral Point, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Chantry Networks, Cytyc, DataSage, Exact Sciences, IDEXX, PerSeptive Biosystems, Somatogen, Telecorp PCS, and TripAdvisor.

Polaris Venture Partners

Established in 1996, with offices in Waltham, Massachusetts and Seattle, Washington, Polaris has over $3 billion under management. Polaris Venture Partners has helped build numerous market leading companies, including Accordant Health Services, Advanced Inhalation Research, Akamai Technologies, Allaire, Alnylam Pharmaceuticals, American Superconductor, Aspect Medical Systems, Avici Systems, Centra Software, Classifieds2000, deCODE genetics, Exchange.com, Matrics, Microbia, Momenta Pharmaceuticals, Paradigm Genetics, Powersoft, PSCI, SolidWorks and TransForm Pharmaceuticals.

Highland Capital Partners

Highland Capital Partners was founded with the mission of helping great people build great companies. Since its inception in 1988, the firm has taken a sector-focused approach to investing in exceptional information technology, communications, and healthcare companies. With more than $2.6 billion of committed capital, Highland has invested in and worked to create such firms as Ask Jeeves, Avid Technology, Be Free, CheckFree, Conor Medsystems, Continental Cable, EXACT Sciences, Lycos, MapQuest, Ocular Networks, Odyssey Healthcare, Sybase, Telica, VistaPrint and WebLine Communications.

Richter Family Fund

The Richter family utilizes the experience and financial resources it generated through 15 years of developing new companies in the medical field, to re-invest in new medical technology ventures. While most of the investments to date have been new ventures based on its own inventions, the fund has also becomes involved in other ventures that it deems as having a significant innovative value.